

Annex A: Amended AVMA Key Terms

This Annex provides an updated overview of key terms of the AVMA approved by the Gavi Board (*Board-2024-Mtg-02-Doc 11b-Annex A: AVMA Base Proposal*) which themselves were updated from (*Board-2023-Mtg-04-Doc 10b - Annex A: AVMA Key Terms*).

2025 Updates are shown in **bold underline**, and are restricted to three additions to the list of priority vaccines overleaf.

Design element	Proposal
Size	Funding requirement of US\$ 750-1,000 million – with the upper end of the range set to accommodate an ambitious outcome for African products in terms of number of incentivised manufacturers and their commercial volumes
Scope	All Gavi Alliance supported vaccines (with differences in payments, see “Incentives”), fill & finish-only (i.e. drug product), and “end-to- end” drug substance + drug product.
Duration	To be <u>launched in June 2024</u> with a proposed duration of 10 years (payments can continue for a period beyond the 10-year mark, depending on tender lengths) ¹
Eligibility	Vaccine Type: Qualifying Vaccine that is WHO Prequalified Manufacturing Type: i) The Qualifying Vaccine is Fully Manufactured on the African continent; or ii) Fill & Finish of the Qualifying Vaccine is carried out in a manufacturing facility on the African continent that is Controlled by the holder of the WHO Pre- Qualification of the Qualifying Vaccine.
Procure- ment pathway	Via successful Gavi-UNICEF tenders and fulfil all other eligibility criteria A potential AU pooled procurement mechanism may be accommodated in the future, subject to determination in line with AVMA’s governance arrangements)
Incentives	Structure <ul style="list-style-type: none"> • Milestone payment at WHO Prequalification • Per-dose accelerator payment, paid per dose, upon delivery of UNICEF tender

Priorities	<p>Platforms: mRNA & Viral Vector ('rapid response platforms')</p> <p>Vaccines:</p> <ul style="list-style-type: none"> • Oral Cholera Vaccine • Malaria • Measles-Rubella (MR) • Hexavalent (wP) • Yellow Fever • Pneumococcal (required profile: min. 13 valent) • Ebola (required profile: indication against 2+ Ebola species and thermostable from –20C) • Rotavirus (required profile: single-dose blow-fill-seal presentation) • <u>Novel Tuberculosis (TB)</u> • <u>Maternal Respiratory Syncytial Virus (RSV)</u> • <u>Mpox (required profile: age 2 years, single dose regimen)</u>
Values	<p>Milestone payment</p> <ul style="list-style-type: none"> • USD 25 million: drug substance manufactured on Priority platform • USD 20 million: drug substance for Priority vaccine • USD 10 million: drug product for Priority vaccine ("fill and finish only") <p>Accelerator payment</p> <ul style="list-style-type: none"> • USD 0.50 per dose: drug substance manufactured on Priority platform • USD 0.50 per dose: drug substance for Priority vaccine • USD 0.40 per dose: all other Gavi-supported drug substance • USD 0.30 per dose: for Gavi-supported drug product (i.e., "fill and finish only") up to a cap of USD 1 per vial
Caps	<ul style="list-style-type: none"> • The total disbursement (Milestone and Accelerator payments across the entire instrument is capped at: • Net funds raised for the AVMA initiative, after deducting operational costs⁵ • USD 300 million per vaccine (pathogen) category / market • USD 250 million for Milestone payments • USD 250 million for "fill and finish only" • The total disbursement (Milestone and Accelerator payments) per manufacturer is capped at: • USD 250 million, of which, USD 50 million for "fill and finish only"